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Abstract
Introduction: The immunoreceptor tyrosine-based activation motif (ITAM) pathway provides osteoclast co-
stimulatory signals and regulates proliferation, survival and differentiation of effector immune cells. In the
osteoclast, the receptors Triggering Receptor Expressed on Myeloid cells 2 (TREM2) and Osteoclast Associated
Receptor (OSCAR) and their respective adaptor proteins, DAP12 and FcRg mediate ITAM signals and induce calcium
signaling and the crucial transcription factor, NFATc1. In rheumatoid arthritis (RA), OSCAR expression by monocytes
is inversely correlated with disease activity. Additionally, serum levels of OSCAR are reduced in RA patients versus
healthy controls suggesting that expression and secretion or cleavage of soluble (s) OSCAR is immune modulated.
Recent data suggest that endothelial cells may also be a source of OSCAR.
Methods: ITAM receptors, their adaptor proteins, and NFATc1 and cathepsin K were detected in human synovial
tissues by immunohistochemistry. Synovial tissues from patients with active RA were compared with tissue from
patients in remission, osteoarthritis (OA) patients and healthy individuals. OSCAR was measured by immunoassay in
synovial fluids recovered from active RA and OA patients. Endothelial cells were cultured with or without 5 ng/mL
TNF-a or IL-1b over 72 hours. Temporal expression of OSCAR mRNA was assessed by qRT PCR and OSCAR protein
in the supernatant was measured by ELISA.
Results: Significantly higher (P < 0.05) NFATc1-positive inflammatory cell aggregates were found in active RA tissues
than in healthy synovial tissue. Similarly, the percentage of OSCAR, FcRg, DAP12 and TREM2 positive cells was
significantly higher in active RA tissues compared to the healthy synovial tissue. Notably, OSCAR was strongly
expressed in the microvasculature of the active RA tissues (9/9), inactive RA (8/9) weakly in OA (4/9) but only in the
lumen of healthy synovial tissue (0/8). OSCAR levels were detected in synovial fluids from both RA (47 to 152 ng/mL)
and OA (112 to 145 ng/mL) patients. Moreover, OSCAR mRNA expression and soluble OSCAR release was stimulated
by TNF-a and IL1-b in cultured endothelial cells.
Conclusions: Increased levels of ITAM related factors were present in synovial tissue from active RA joints
compared to OA and healthy joints. OSCAR was strongly expressed by the vasculature of active RA patients and
membrane bound and soluble OSCAR was stimulated by inflammatory mediators in endothelial cells in vitro.
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Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that
involves dysregulated immune cell functions. It is charac-
terized by joint damage and systemic bone loss associated
with excessive osteoclast activity [1-4]. Human studies
show that mature osteoclasts are in close proximity to the
bone surface in affected joints of patients with RA [2].
Identifying factors that regulate the differentiation and
activity of osteoclasts is crucial in identifying potential tar-
gets to abrogate this local and systemic bone loss in RA.
A key molecule known to stimulate osteoclast differen-
tiation and activity is receptor activator NF kappa B
ligand (RANKL). Elevated RANKL in active RA relative
to its inhibitor osteoprotegerin (OPG) is associated with
increased osteoclast differentiation and resorption [5]. In
active RA synovial tissue we, and others, have demon-
strated that RANKL expression is significantly increased
in lymphocytes and fibroblasts [6,7]. RANKL binds to its
receptor, RANK, on osteoclast precursors instigating the
differentiation of monocytes into multinucleated mature
osteoclasts via activation of key signaling cascades invol-
ving the transcription factor, nuclear factor of activated T
cells (NFATc1) (reviewed by Asagiri et al. [8]).
NFATc1 is not only crucial in the regulation of terminal
osteoclast formation, but also plays a role in the immune
system [8,9]. NFATc1 also regulates T cell differentiation
and activation [10], such as that seen in inflammatory dis-
eases such as RA. In osteoclasts, NFATc1 directly induces
early and late stage osteoclast specific gene expression in
the absence of RANKL [9,11-14]. To our knowledge the
distribution of NFATc1 expression in synovial tissue from
active RA joints has not been previously characterized.
Recent studies suggest RANK-RANKL induced osteo-
clastogenesis is enhanced by co-stimulatory signals
mediated by immunoreceptor tyrosine-based activation
motif (ITAM) harboring adaptors [15-17]. ITAM signal-
ling is also involved in the regulation of effector immune
cells proliferation, survival and differentiation [16,17].
DNAX-activating protein 12kDa (DAP12) and Fc recep-
tor common g chain (FcRg) are similar ITAM-containing
adaptor proteins relevant to osteoclast formation in phy-
siological bone turnover [17-19]. In pre-osteoclasts and
osteoclasts the ITAM adaptor proteins DAP12 and FcRg
associate with innate immune receptors; in particular,
Triggering Receptor Expressed on Myeloid cells 2
(TREM2) [15,20-22] and Osteoclast Associated Receptor
(OSCAR) [17,23], respectively, to activate calcium, induce
NFATc1 and convey ITAM signaling [17].
Mice deficient in both DAP12 and FcRg develop severe
osteopetrosis [16] and exhibit an osteoclast multinuclea-
tion defect that is restored upon introduction of NFATc1
[17]. Evidence suggests DAP12 and TREM2 are required
for differentiation and migration of osteoclasts as bone
resorption is reduced in osteoclasts derived from mice
with mutations in DAP12 and/or TREM2 in vitro
[15,20,21]. In the context of RA, activation of macro-
phages by FcRg is reported to induce cartilage destruc-
tion independent of inflammation [24]. It was thus
suggested that interaction of FcRg with immune com-
plexes drives inflammation and induces bone loss indir-
ectly [24]. We have recently demonstrated increased
levels of OSCAR, FcRg, TREM2 and DAP12 in peri-
implant tissues [25]. To our knowledge the expression of
FcRg, DAP12 and TREM2 has not yet been demonstrated
in human RA.
A single-nucleotide polymorphism within the promo-
ter of the OSCAR gene has been linked to increased
risk of postmenopausal osteoporosis [26]. In RA,
OSCAR has been related to disease activity [27] and the
potential of cells to differentiate into osteoclasts [28].
These findings support the contention that OSCAR
plays a role in human bone turn over [26,28,29]. In
osteoclasts the crucial transcription factor, NFATc1,
induces OSCAR gene expression [30]. Furthermore,
ligand-activated OSCAR interacts with FcRg to produce
an increase in intracellular calcium [31] that further sti-
mulates NFATc1 expression. This establishes a positive
feedback loop that results in marked elevation of both
OSCAR and NFATc1 expression in terminal stages of
osteoclast formation [8]. Administration of an OSCAR-
Ig fusion protein inhibits osteoclastogenes in vitro
[30,32]. These findings establish OSCAR as not only an
important immune modulator but also a major player in
the regulation of osteoclastogenesis.
OSCAR is expressed by osteoclasts as well as dendritic
cells in humans and is involved in antigen presentation
and activation of dendritic cells [33,34]. OSCAR has also
been reported to be associated with osteoclasts near sites
of erosion and the mononuclear cells adjacent to the
microvasculature in RA patients [28]. Interestingly, more
recent studies have identified OSCAR expression by
endothelial cells [35]. This is similar to our observation
that OPG expression and release by endothelial cells is
regulated by inflammatory cytokines [36]. However, pro-
duction and possible release of soluble OSCAR by
endothelial cells in response to inflammatory cytokines
present in arthritides has not yet been reported.
High levels of OSCAR have recently been demon-
strated in the synovial tissues and monocytes isolated
from RA patients, with these cells having a greater pro-
pensity for differentiation into osteoclasts [28]. Tumor
necrosis factor (TNF)-a was found to induce OSCAR
expression in monocytes isolated from RA patients [28].
However, serum levels of OSCAR were lower in RA
patients compared with normal controls. These findings
further suggest cell associated and soluble OSCAR is
regulated by inflammatory cytokines that play a signifi-
cant role in the pathogenesis of RA.
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We aimed to investigate the distribution of ITAM recep-
tors (OSCAR and TREM2) and their adaptor proteins
(FcRg and DAP12) in synovial tissues from patients with
active RA (as yet untreated with disease modifying anti-
rheumatic drugs (DMARDs) and inactive RA (patients in
remission following treatment) compared with tissues
from OA and healthy joints. We also aimed to assess
whether OSCAR is detectable in synovial fluid from active
RA and OA as its close proximity to the joint might better
reflect localized disease activity. In addition to this, we
sought to determine whether OSCAR is expressed and
released by endothelial cells in vitro and whether this
expression is regulated by inflammatory cytokines.
Materials and methods
Patient samples
Synovial tissue samples were obtained from the rheuma-
tology unit in the Repatriation General Hospital, Daw
Park, South Australia. RA patients fulfilled the American
College of Rheumatology criteria for RA [37]. Active RA
patients were yet to undergo DMARD treatments and
had active joint inflammation while inactive RA patients
were in remission after successful DMARD treatment
and undergoing follow-up. A small-bore arthroscopy (2.7
mm arthroscope, Dyonics, Andover, MA, USA) was per-
formed under local anesthesia, as previously described
[38]. Biopsies of synovial tissues from RA patients were
obtained from all accessible regions of the knee joint, but
mainly from the suprapatellar pouch. OA samples were
obtained at the time of knee replacement surgery and ful-
filled published criteria [39]. Healthy samples were from
patients attending a sports medicine clinic with unex-
plained knee pain at the time of a diagnostic arthroscopy
[40]. Details of the patients and medication at the time of
surgery are summarized in Table 1. The study protocol
was approved by the institutional Medical Ethics Com-
mittee. Written informed consent was obtained from
patients with diseased (OA, active and inactive RA) and
healthy joints that were included in the study.
Tissues were fixed in 10% buffered formalin and
embedded in paraffin. Five-micrometer sections were
mounted on 3-aminopropyltriethoxy-silane (APTS)
(Sigma, St. Louis, MO, USA) coated glass slides for




Serial sections were stained with the following antibodies
(Mab): mouse monoclonal IgG1 anti-NFATc1 ((clone 7A6,
sc-7294) Santa Cruz Biotechnology, Santa Cruz, CA, USA)
(4 μg/mL), goat polyclonal anti-human OSCAR (sc-34233,
Santa Cruz Biotechnology) (10 μg/mL), rabbit polyclonal
anti-human FC€R1G (LS-B2169, Lifespan Biosciences,
Inc., Seattle, WA, USA) (1.25 μg/mL), rabbit polyclonal
anti-human TREM2 (HPA010917, Sigma-Aldrich Pty.
Ltd., Castle Hill, NSW, Australia) and rabbit polyclonal
anti-human DAP12 (sc-20783, Santa Cruz Biotechnology)
(2 μg/mL). A mouse monoclonal IgG1 anti-human cathe-
psin K (Cath K) (MAB3324 clone 182-12G5, Millipore
(Billerica, MA, USA) (2 μg/mL) was used to detect the
presence of any osteoclasts.
Secondary antibodies included 10 μg/mL polyclonal goat
anti-mouse IgG (Dako Cytomation, Glostrup, Denmark),
or 3 μg/mL goat anti-rabbit IgG (P0448, Dako, Glostrup,
Denmark) or 7 μg/mL swine anti-goat IgG (ACI3404, Invi-
trogen Life Technology, CA, USA). Tertiary antibodies
included 7 μg/mL swine anti-goat IgG (ACI3404, Invitro-
gen Life Technology) or 13 μg/mL rabbit anti-swine IgG
(P0164, Dako, Glostrup, Denmark).
Immunohistochemistry (IHC)
Sections were dewaxed and pre-treated with either 10
mM sodium citrate buffer pH 6.0 or 10 mM Tris-ethyle-
nediamine-tetraacetic acid (EDTA) buffer pH 9.0 at 90
to 95°C for 10 to 20 minutes for antigen retrieval. Sec-
tions were treated with phosphate buffered saline (PBS)/
0.1% sodium azide and 0.3% v/v hydrogen peroxide to
Table 1 Details of the patients and medication at the time of surgery
Groups Active RA Inactive RA OA Normal
Age (years) 62.5 ± 19.28 72.33 ± 7.07 69.22 ± 7.98 36.3 ± 10.39
Gender (male/total) 2/10 6/9 6/9 6/10
CRP (IU/mL) 83.90 ± 83.78 9.78 ± 8.21 NA NA
RF (mg/L) 19.40 ± 44.10 1.44 ± 0.53 <20 NA












CRP, C-reactive protein; DMARD, disease modifying antirheumatic drug; Im Gold, intramuscular sodium aurothiomalate; MTX, methotrexate; NSAIDs, non-steroidal
anti-inflammatory drugs; RF, rheumatoid factor; SSZ, sulphasalazine
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inhibit endogenous peroxidase activity. A three-step per-
oxidase-based immunostaining technique, as previously
described [41], with minor modifications, was employed.
Sections were incubated with the primary antibodies
(concentrations as described above) diluted in PBS and
1% bovine serum albumin (BSA) overnight at room tem-
perature in a wet chamber. Sections were incubated with
the appropriate HRP-conjugated secondary antibodies
followed by incubation with the relevant HRP- conju-
gated tertiary swine anti-goat IgG or rabbit anti-swine
IgG. HRP activity was detected using hydrogen peroxide
as the substrate and 3-amino-9-ethylcarbazole (AEC)
(K3469, Dako, Carpinteria, CA, USA) as the dye. Sec-
tions were counter-stained with Harris hematoxylin and
lithium carbonate and mounted with GurrAquamount
(British Drug House, Poole, UK). Negative controls
included isotype-matched antibody controls (mouse
IgG1kappa for mouse IgG1) and antibody-raised serum
for polyclonal antibody (normal rabbit serum or goat
serum) with equivalent concentration to the primary
antibodies.
Semi quantitative scoring analysis (SQA) of IHC result
Sections were scanned at high resolution using a Nano-
Zoomer (Hamatsu, Shizouka, Japan), Digital Pathology,
to enable quantification and archival of the IHC results.
Three areas of 2 mm2 were randomly selected and sec-
tions were assessed in random order by two blinded
observers. Semi-quantitative assessment (SQA) of
OSCAR, FcRg, DAP12 and TREM2 and Cath K staining
was scored using a 5-scale (0 to 4) scoring system
[25,42]. Assessment was according to the percentage of
positive stained cells as follows; 0 represented 0 to 5%,
1 for 6 to 10%, 2 for 11 to 25%, 3 indicated between 26
and 50% and a score of 4 indicated more than 50% of
positive cells (adapted from [42]) within the sublining of
the synovial tissue. For NFATc1 immunostaining, the
number of positive stained cell aggregations (defined as
more than 25 cells) was used as a parameter for grading
(adapted from [43]). A score of 0 represented no positive
stained cell aggregation, a score of 1 indicated one to
three positive cell aggregations, score of 2 indicated total
positive cell aggregation between four and six, seven to
nine positive cell aggregations gave a score of 3 and a
score of 4 indicated more than nine positive cell aggrega-
tions were present. Observations were made as to the
presence of positive cells in the vessels or lining.
Endothelial cell in vitro cultures
Bone marrow endothelial cells (BMEC) were cultured in
triplicate in the presence and absence of 5 ng/mL TNF-a
and IL1-b over a 72-hour time period. Expression of
OSCAR and OPG mRNA levels by BMECs were assessed
at 0, 6, 12, 24, 48 and 72 hours by quantitative reverse
transcriptase polymerase chain reaction (QRT PCR).
Only data from 0, 24, 48 and 72 are presented here.
Supernatants were collected at 0, 24, 48 and 72 hours to
assess soluble OSCAR and were stored at -20°C until use
in ELISA assay. BMECs were also cultured on chamber
slides for immunofluorescent detection of OSCAR and
OPG.
ELISA analysis of soluble OSCAR
Synovial fluid was obtained from patients at the rheuma-
tology unit in the Repatriation General Hospital, Daw
Park, South Australia. The patient cohort consisted of
synovial fluid from active RA (average age 67, CRP 67.4
IU/mL and RF 165 mg/L, 7 male/5 female, 4/12 with ero-
sion) and OA joints (average age 70, 3 male/5 female).
Levels of OSCAR were assessed by ELISA kit following
manufacturer’s instructions (USCN Life Science, Inc.,
Wuhan, China). Samples (synovial fluids and supernatants)
were clarified by centrifugation at 13,000 rpm for five min-
utes at 4°C. The supernatant was transferred to 1.5 mL
eppendorf tubes and diluted 1/5 for synovial fluid and
1/10 for supernatant in the sample diluent provided in the
kit. One hundred microliters of pre-diluted samples were
loaded into each well along with the protein standards
provided. Assays were carried out in duplicate and the
OSCAR protein concentration in each sample was deter-
mined based on the standard curve generated.
RNA extraction and cDNA synthesis
Total RNA was isolated from in vitro BMEC cultures fol-
lowing the addition of 500 μL TRIzol reagent per well, as
per the manufacturer’s instructions (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA). Complementary DNA
(cDNA) was synthesized from 1 μg RNA per reaction
using Superscript III Reverse Transcriptase (Invitrogen
Life Technologies), as previously described [44].
Quantitative real time reverse-transcription polymerase
chain reaction (QRT-PCR)
Real-time PCR was performed using Platinum SYBR
Green qPCRSupermix-UDG (Invitrogen Life Technolo-
gies), as per the manufacturer’s recommendations. Ampli-
fication was carried out in a Rotor-Gene 3000. Reaction
mixtures contained 1 μl of 1 in 5 pre-diluted cDNA, 7.5 μl
Platinum SYBR Green qPCR Supermix-UDG, 300 nM
each of forward and reverse primers and diethyl pyrocar-
bonate (DEPC)-treated water to a final volume of 15 μl.
Primer3Plus freeware [45] was used to design oligonucleo-
tide primers to human OSCAR Forward ‘CCC AGC TTC
ATA CCA CCC TA’ and Reverse: ‘GAA GAG AAG GGG
AGC GAT CT’ [46]. Primer sequences for OPG and the
endogenous reference gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were designed as described pre-
viously [47]. All samples were investigated in triplicate
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QRTPCR reactions. Fold induction was calculated as a
measure of 2ddCT [48].
Immunofluoresence of BMEC
BMECs were grown for 40 hours in the absence or pre-
sence of 5 ng/mL IL-1b or TNF-a. Cells were fixed with
1:1 methanol:acetone for five minutes and washed with
PBS. Primary antibodies OPG MAB805 (10 μg/mL) or
polyclonal goat anti-human OSCAR (8 μg/mL, sc-34233,
Santa Cruz Biotechnology) were diluted in PBS with 1%
BSA and incubated overnight at room temperature. To
control for non-specific staining of the OSCAR antibody,
wells were incubated with normal goat serum in the
absence of the antibody to OSCAR. Following washing
with PBS, OSCAR and OPG antibodies were detected
with secondary antibodies to goat conjugated with FITC
(green) and mouse conjugated to cy3 (red) (both from
Southern Biotechnology Associates, Inc., Birmingham, AL,
USA), respectively, diluted in PBS plus 1% BSA for 30 min-
utes then washed three times with PBS.
Statistical analysis
Power calculations demonstrate sufficient power to detect
differences between the healthy subjects and joints with
active RA for each of the molecules detected (92.9 to
100%). To assess the SQAs assigned by analysis of the IHC
staining statistical analysis was performed using SPSS ver-
sion 11.5 (SPSS Inc, Chicago, IL, USA). A non-parametric
Kruskal-Wallis analysis was used to compare the mean of
the SQA score between the groups. A Mann-Whitney-U
test was used to examine the significant difference
between two groups, with a P-value <0.05 accepted as
statistically significant.
Differences in the soluble OSCAR levels in synovial
fluids between the two groups were analyzed by Student’s
t-test and P < 0.05 was considered significant. Statistical
significance between treatments and time points was
determined using Kruskal-Wallis followed by the Mann-
Whitney test using GraphPad Prism version 5.0d (Graph-
Pad Software Inc. La Jolla, CA, USA).
Differences in mRNA levels between the groups at each
time point were analyzed using a Two-way Anova test.
Results
Expression of ITAM modulatory factors in active RA
While NFATc1 expression was localized in isolated cells
throughout the tissue, NFATc1 was mainly expressed by
cells within lymphocyte aggregates in tissues from
untreated active RA joints (Figure 1). The SQA grading
for NFATc1 immunostaining was, therefore, based on
the number of cell aggregates expressing NFATc1
(described in Methods). The number of NFATc1-positive
cell aggregations was found to be significantly more in
the active RA group compared to all other groups (P <
0.05) (Table 2).
Cathepsin K (Cath K) is routinely used as a marker of
osteoclast-like cells as it is expressed at high levels in
osteoclasts [49,50] and is the main bone-matrix degrading
enzyme [51,52]. Immunostaining for Cath K was found to
be predominantly in the sublining of the synovium and
expressed by synovial fibroblasts (images not shown). The
proportion of Cath K positive cells was not significantly
different between groups.
OSCAR has been reported to be increased in RA com-
pared to that in OA tissues [28]. OSCAR expression was
associated with macrophage-like cells in the sublining of
the synovium of inactive and active RA patients as well
as in the lining of OA patients (Figure 1). Strongly posi-
tive OSCAR staining was associated with the microvascu-
lature of the synovium in patients with active RA, nine of
nine (Figure 2A) and with inactive RA (eight of nine)
(Figure 2B). OSCAR was weakly expressed in four out of
eight of the tissue samples from OA patients (Figure 2C)
and was absent in the microvasculature of the healthy tis-
sues (zero of nine) (Figure 2D). Interestingly, OSCAR
appeared in the lumen of the microvasculature of the
synovium from healthy patients that was suggestive of
cleaved or soluble protein in the serum.
TREM2 was highly expressed throughout tissue from
active RA patients (Figure 1). Many types of cells
appeared to express TREM2, including mononuclear
cells in lymphoid aggregates and fibroblasts with expres-
sion significantly greater than all other groups (Table 2).
TREM2 expression was also associated with the micro-
vasculature of active and inactive RA patients.
FcRg was also highly expressed in active RA tissues
and OA patient tissues (Figure 1). This was significantly
higher in comparison to the inactive RA and the control
tissues (P < 0.05) (Table 2). FcRg was strongly expressed
in macrophage-like synovial lining cells particularly in
the OA patients. In active RA, FcRg appeared to be
expressed by macrophage and fibroblast-like cells
throughout the tissue but was absent in the lymphoid
aggregates and not associated with the microvasculature.
DAP12 expression was significantly higher in active
RA compared with all other groups (P < 0.05) (Table 2).
DAP12 appeared predominantly associated with macro-
phage-like cells in the sublining of the synovial tissue
and the macrophage-like lining cells of the OA group
(Figure 1). Of note, the microvasculature was negative
in all groups.
Soluble OSCAR in OA and RA synovial fluid
Soluble OSCAR was detected in serum from RA
patients and normal individuals by Herman [28], sug-
gesting a cleaved or released form of OSCAR. To more
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closely assess OSCAR in relation to disease activity near
the joint, we measured soluble OSCAR in the synovial
fluid from OA (average age 70, 3 male/5 female) and
RA patients (average age 67, 7 male/5 female). We
detected soluble OSCAR in OA, (112 to 145 ng/mL)
with more variable levels in active RA groups (47 to 152
ng/mL) and no significant difference between the groups
(Figure 3).
Figure 1 Expression of NFATc1 and ITAM associated molecules in human synovial tissues. Detection of factors was visualised with AEC
(red) and counterstained with heamatoxilyn (blue) 100X mag.
Table 2 Semi-quantitative analysis of staining for NFATc1 and ITAM factors within tissue
Act RA Inact RA OA Norm
















































Mean Score ± SEM; ♦ P < 0.05 significantly different from Inactive RA, ‡ P < 0.05 significantly different from OA, ◘ P < 0.05 significantly different from Normal.
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OSCAR expression in BMECs
OSCAR expression by human umbilical vein endothelial
cells (HUVEC) has been recently reported [35]. In our
IHC analysis, we observed high levels of OSCAR asso-
ciated with the microvasculature in the sublining region
of synovial tissue from active and inactive RA synovial
tissue joints (Figure 2A, B), with low levels associated
with OA microvasculature (Figure 2C). It was interesting
to observe that OSCAR was present in the lumen of the
microvasculature in the synovium of normal patients
(Figure 2D). These findings suggest soluble OSCAR may
be present that is likely mediated by inflammatory cyto-
kines present in RA tissue [53]. In view of this, we
assessed whether OSCAR mRNA expression and release
of soluble OSCAR by endothelial cells was modulated
by inflammatory mediators associated with RA. OSCAR
mRNA was significantly increased in cultured endothe-
lial cells by IL-1b at 48 and 72 hours (P < 0.05 and
0.001 respectively) and TNF-a at 48 and 72 hours
(P 0.001) compared with untreated cells at these time
points (Figure 4A). Similarly, TNF-a and IL-1b signifi-
cantly increased OPG expression by BMECs both at 48
and 72 hours (P < 0.001), consistent with our previous
report using HUVEC cells [36] (Figure 5B). Based on
these findings, supernatants from the cytokine stimu-
lated BMEC cultures were assessed for OSCAR protein
after 24, 48 and 72 hours of treatments (Figure 4C). We
found increasing levels of soluble OSCAR over a 72-hour
time period in response to both TNF-a and IL-1b with
P < 0.001 at all time points compared with untreated
BMECs.
Confocal detection of OSCAR in BMECs
To ascertain whether cell bound OSCAR is regulated by
inflammatory cytokines, OSCAR was detected by immu-
nofluorescence in cytokine stimulated BMECs. This was
compared to OPG in the light of our previous findings
that showed OPG is up-regulated by TNF-a in endothe-
lial cells [36]. Following IL-1b treatment, little OSCAR
but higher levels of OPG were detected (Figure 5B, E,
respectively). TNF-a induced strong protein expression
of OSCAR and little OPG expression. OSCAR appeared
to be present in vesicles as there was strong punctate
staining as well as diffuse cellular staining (Figure 5C). In
all the treatments, the pattern of OSCAR expression was
distinctly different from that of OPG.
Figure 2 OSCAR staining in associated with the vasculature in active (A) and inactive RA (B) synovial tissues as well as OA (C) and
normal synovial tissues (D) (red stain) at 200X mag.
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Discussion
ITAM-related molecules are likely to be important med-
iators of RA joint destruction through their regulation
of immune-mediated inflammation and bone erosion by
osteoclasts [29]. In osteoclasts, the ITAM co-stimulatory
pathways activate calcium and induce NFATc1 in pre-
osteoclasts [17] to further enhance osteoclast differentia-
tion and activation [9]. NFATc1 in activated T-cells reg-
ulates their differentiation and activation [10] and may
further stimulate osteoclastogenesis via stimulating
RANKL expression [54]. We observed significantly
increased aggregates of NFATc1 positive cells in active
RA synovial tissue. These are likely to represent popula-
tions of activated T-cells in the rheumatoid tissues.
While low numbers of NFATc1 positive cells with the
morphology of multinucleated pre-osteoclasts were
observed in the current study, this may be due to the
tissue sections not including juxtaposing bone where
later stage active osteoclasts would be present [55].
Furthermore, our samples consisted of synovial tissue
rather than pannus where osteoclast precursors are
higher in number [2]. For similar reasons we did not
note a significant increase in osteoclast-like cells expres-
sing Cath K in active RA synovial tissue. Additionally,
we observed Cath K associated with fibroblasts, consis-
tent with published reports describing Cath K expres-
sion in skin fibroblasts [56,57]
Consistent with the findings reported here, TREM2 has
been reported as expressed by macrophages, osteoclasts
and, more recently, endothelial cells [15,22,58]. The
ITAM-containing adapter molecule, DAP12, associates
with TREM2 receptors in a number of cell types, includ-
ing osteoclasts [15,20,22,59]. DAP12/TREM2 signaling
has been shown to regulate inflammatory responses [59],
play an important role in antigen presentation by dendri-
tic cells [20] and has been implicated in T cell regulatory
activity [60]. We observed markedly higher levels of
DAP12 and TREM2 in active RA patients. Multiple cell
types expressed TREM2, including mononuclear cells in
lymphoid aggregates and fibroblasts. TREM2 expression
was also associated with the microvasculature of active
and inactive RA patients. Interestingly, DAP12 appeared
Figure 3 Levels of soluble OSCAR in synovial fluids from RA and OA patients as measured by ELISA. Each point represents levels in an
individual patient.
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predominantly associated with macrophage-like cells in
the sublining of the synovial tissue, particularly in the
macrophage-like cells in the lining of the OA group.
OSCAR and FcRg form an ITAM receptor/signaling
pair that is expressed in osteoclasts and transmits ITAM
signaling to induce osteoclast differentiation [16,23]. We
observed high levels of FcRg in association with fibro-
blasts and monocytes of the synovial sublining while
lymphoid aggregates and the vasculature did not express
FcRg. Of note, similar to DAP12, FcRg was associated
with macrophage-like synoviocytes in the synovial lining
with some scattered monocytes in the sublining of the
OA tissue. The increased DAP12 and FcRg expression
may indicate a role in the pathogenesis of OA but this
is yet to be determined.
OSCAR is a functional receptor on monocytes and
neutrophils involved in the induction of the primary
pro-inflammatory cascade and the initiation of down-
stream immune responses [31]. Ligation of human
OSCAR on monocytes and neutrophils also results in
the induction of a pro-inflammatory cascade and down-
stream immune responses [31]. High levels of OSCAR
have recently been demonstrated in the tissues of RA
patients and the serum of healthy individuals [28]. This
is consistent with our findings that OSCAR protein was
increased on monocytes from RA patients compared
with healthy individuals with expression correlating with
inflammatory disease activity [28].
Figure 4 Expression of OSCAR by endothelial cells in response
to inflammatory cytokines. BMECs were cultured in triplicate in
the presence or absence of recombinant TNF-a and IL1-b. A.
OSCAR gene expression was assessed at 0, 24, 48 and 72 hours by
QRT PCR. GAPDH was used as the housekeeping gene. Fold
induction was calculated as a measure of 2ddCT. B. Induction of OPG
gene expression at 0, 24, 48 and 72 hours. C. Release of soluble
OSCAR was assessed in duplicate, by ELISA, as per the
manufacturer’s instructions. The mean values were calculated.
Significance of P < 0.05 (*) and P < 0.001 (#) are indicated.
Figure 5 OSCAR and OPG expression by BMECs. BMECs were cultured in the absence (A and D) or presence of 5 ng/mL IL-1b, (B, E) and 5
ng/mL TNF-a (C, F) for 40 hours and fixed for visualization by con-focal microscopy. OSCAR is seen as green (A, B, C) and OPG as red (D, E, F).
Original magnification was 200X.
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Interestingly, OSCAR expressing monocytes were seen
adjacent to microvasculature, consistent with observa-
tions by Herman et al. [28]. In a previous study, the
expression of OSCAR was shown in multinucleated
osteoclast-like cells attached to the bone [28]. We could
not confirm this as the synovial tissue specimens from
the RA patients used in this study did not include bone
[55,61]. However, we did detect positive macrophage-like
cells expressing OSCAR in the lining of the OA speci-
mens similar to that previously reported [28]. Herman
and colleagues have suggested that OSCAR expression
might be regulated by pro-inflammatory cytokines [28].
Therefore, increased expression of OSCAR in active RA
synovia compared to other groups is likely to be due to
elevated inflammatory cytokines present in RA synovial
tissues.
A possible limitation of the study is that both groups
were not perfectly age- and sex-matched. It is very difficult
to age- and sex-match the RA, OA and normal tissues due
to the nature of the joint diseases affecting predominantly
different age groups and sexes. In addition, patients pre-
senting with active RA can take several years of treatment
before the disease is in remission and classified as inactive.
While to our knowledge there is are no reports that
OSCAR expression changes with age, it is possible the dif-
ferences in age may influence the results of our study.
It is possible that soluble OSCAR may act as a decoy
receptor and suppress ITAM signaling. Of particular
interest is the observation that RA patients had reduced
levels of soluble OSCAR in serum compared to healthy
individuals [28]. However, we noted high levels of
OSCAR in the synovial fluid of our active RA patients
and OA patients. A possible reason for this is that in the
Herman et al. study patients with RA were being treated
with anti-TNF therapy, unlike our active RA patients. It
is also possible that levels in the joint locally are not
necessarily reflected systemically in the circulation. The
lack of significant differences between soluble OSCAR in
OA and RA patients may be due to the low sample num-
ber or may reflect the increased release of OSCAR in
response to inflammatory cytokines present in both of
these pathologies [38,53].
High levels of OSCAR were associated with the micro-
vasculature of the synovium of active RA specimens as
well as tissues taken from our inactive RA patient group,
who have had successful DMARD treatments. In the
synovial tissue of healthy joints, positive OSCAR staining
was present only in the lumen of the vasculature, sug-
gesting the presence of soluble OSCAR in the blood.
These observations were consistent with the recent find-
ing that human primary endothelial cells express OSCAR
[35]. Contrary to our findings, Herman et al. did not
observe OSCAR staining of the microvasculature of his
RA patients. This again may be due to the fact that,
unlike our active RA patients, the patients in the Herman
study were being treated with anti-TNF therapy.
The increased expression of OSCAR associated with
the microvasculature in RA compared with normal tis-
sue suggests that OSCAR expression is modulated by
immune mediators or cytokines. Our previous studies
have shown a reverse pattern of OPG expression in the
vasculature, with low OPG levels associated with RA,
compared with high levels associated with normal tissue
[41]. Additionally, our in vitro studies showed that OPG
expression in HUVEC is regulated by cytokines [36].
Our in vitro studies extend the findings by Goettsch et
al. [35] and demonstrate that the expression of OSCAR
by endothelial cells is stimulated by the inflammatory
cytokines, TNF-a and IL-b, and is consistent with our
in vivo findings showing OSCAR expression was ele-
vated in the untreated RA synovial vasculature. Impor-
tantly, endothelial cells are a likely source of OSCAR
and not just binding soluble OSCAR present in the
serum, as we demonstrated that the inflammatory cyto-
kines stimulated both mRNA and protein in vitro. TNF-
a also induces OSCAR expression in monocytes in vitro
[28]. This indicates that soluble OSCAR in the serum
[28] and synovial fluid in RA is released by a variety of
cells and is stimulated by inflammatory cytokines.
As recombinant human OSCAR-Fc is able to act as a
decoy receptor for cell bound OSCAR [28], soluble
OSCAR might provide a protective mechanism against
bone erosion in vivo by competing with a ligand for cellu-
lar OSCAR and reducing signaling for inflammatory cells
and osteoclasts. We propose that successful treatment of
RA results in increased cleavage of OSCAR resulting in
increased soluble OSCAR levels [27,28]. This is consistent
with the observation that patients in remission have higher
levels of soluble OSCAR and suggests a role in modulating
osteoclastic bone resorption.
While we were able to demonstrate OSCAR expression
in RA and OA synovial fluids for the first time, our data
on the relative levels suggest that it is not a good discrimi-
nator between RA and OA. The data of Herman [28] and
Zhao [27], who measured blood levels, suggest blood levels
are lower in active RA compared to inactive disease. How-
ever, induction of OSCAR release in vitro and the levels of
expression in the tissue indicate its expression, at least
locally, may be related to disease activity. Further studies
following patients during treatment may help resolve
whether it is a marker for assessing disease activity and
joint erosion in RA.
Conclusions
Here we present evidence that NFATc1 and the ITAM-
related molecules FcRg, TREM2, DAP12 and NFATc1 are
up-regulated in active RA synovia in comparison to
healthy control or inactive RA and OA tissues. In addition
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to this, we find higher proportions of OSCAR positive ves-
sels in both active RA patients and inactive RA patients
compared with healthy controls. Our in vitro studies also
confirm OSCAR expression by endothelial cells and
demonstrate regulation of production and release of solu-
ble protein by inflammatory cytokines, IL-1b and TNF-a.
Of interest, we were able to demonstrate OSCAR expres-
sion in RA and OA synovial fluids for the first time.
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